A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: Add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 540-543

  Takeuchi, Hiroyoshi ^a,b   Suzuki, Takefumi ^a,c   Uchida, Hiroyuki ^a,d,e   Nakajima, Shinichiro ^a,b   Nomura, Kensuke ^a,f   Kikuchi, Toshiaki ^b   Manki, Hiroshi ^b,f   Watanabe, Koichiro ^a,b   Kashima, Haruo ^b  

^a Oizumi Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c Inokashira Hospital   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f Komagino Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MALE; OPEN STUDY; PATIENT ATTITUDE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; EXTRAPYRAMIDAL SYNDROME; HOSPITALIZATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 58149107588     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181842586     Document Type: Article

References (17)

1. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
2. Raja M. Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int JNeuropsychopharmacol. 2007; 10:107-110.
3. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol. 2004;19:45-48.
4. Sullivan G, Bienroth M, Jones M, et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin. 2007;23:1733-1744.
5. Cassano GB, Fagiolini A, Lattanzi L, et al. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy. Clin Drug Investig. 2007;27:1-13.
6. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391-399.
7. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well- being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68:75-80.
8. Inagaki A, Inada T, Fujii Y. Dose Equivalents of Psychotropic Drugs. Tokyo, Japan: Seiwa Press; 1999. [in Japanese].
9. Watanabe M, Matsumura H. Reliability and validity of Subjective Well- being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J). Jpn J Clin Psychopharmacol. 2003;6:905-912.
10. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression- Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003;416: 16-23.
11. Inada T, Yagi G. Current topics in neuroleptic-induced extrapyramidal symptoms in Japan. Keio J Med. 1996;45:95-99.
12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
13. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology. 2000;152:174-180.
14. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114:3-13.
15. Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry. 2007;68: 406-409.
16. Weiden PJ, Aquila R, Dalheim L, et al. Switching antipsychotic medications. J Clin Psychiatry. 1997;58(suppl 10):63-72.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.